(NASDAQ: ELDN) Eledon Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.81%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 35.93%.
Eledon Pharmaceuticals's earnings in 2026 is -$45,617,000.On average, 6 Wall Street analysts forecast ELDN's earnings for 2026 to be -$68,471,349, with the lowest ELDN earnings forecast at -$97,378,441, and the highest ELDN earnings forecast at -$57,343,902. On average, 5 Wall Street analysts forecast ELDN's earnings for 2027 to be -$67,826,610, with the lowest ELDN earnings forecast at -$67,644,566, and the highest ELDN earnings forecast at -$65,308,333.
In 2028, ELDN is forecast to generate -$78,142,444 in earnings, with the lowest earnings forecast at -$75,078,034 and the highest earnings forecast at -$80,440,751.